http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20150000247-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6171684de68ce62ef3fbf1655618249 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0008 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
filingDate | 2013-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5f231a331fbb997bc798597abbcf81f |
publicationDate | 2015-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-20150000247-A |
titleOfInvention | Composition for Enhancing Sensitivity to Anti-cancer agent Comprising of ZMYM2 |
abstract | The present invention relates to a composition for enhancing the sensitivity of an anticancer agent, more specifically, a zinc finger, MYM-type 2 (ZMYM2) protein; Or an expression vector containing a polynucleotide encoding ZMYM2 as an active ingredient; And a polynucleotide encoding ZMYM2 protein or ZMYM2 as an active ingredient. Since ZMYM2 (zinc finger, MYM-type 2) according to the present invention has a function related to the sensitivity enhancement of sorafenib to cancer cells, it is possible to control the tolerance of the anticancer drug sorapenib to cancer cells , The use of low concentration of sorapenib can inhibit the growth of cancer cells or induce death, and thus can be usefully used in cancer therapy. |
priorityDate | 2013-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 851.